Protein Expression Systems Market Five Years Forecast Skeleton With Key Companies Agilent Technologies, Inc., Becton, Dickinson & Company, Lonza Group, GenScript Biotech Corporation, Bio-Rad Laboratories

The global protein expression systems market size was valued at US$ 1.2 billion in 2017, and is expected to witness a CAGR of 11.1% over the forecast period (2018 – 2026).

The Global Protein Expression Systems Market, By Expression System (Mammalian Expression Systems, Insect Expression Systems, Bacterial Expression Systems, Plant Expression Systems, Yeast Expression Systems, and Cell Free Expression Systems), By Product Type (Competent Cells, Instruments, Reagents, and Others), By Application (Protein Therapeutics and Research Studies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 1.2 billion in 2017, and is projected to exhibit a CAGR of 11.1% over the forecast period (2018 - 2026), as highlighted in a new report published by Coherent Market Insights.

The production of proteins in appropriate quantity and quality is an essential requirement of the biopharmaceutical and biotechnology industry. Therapeutic proteins provide important therapies for a variety of diseases such as anemia, diabetes, cancer, infectious diseases, and hemophilia. There is a growing demand for recombinant proteins for therapeutic applications. Common therapeutic proteins include antibodies, anticoagulants, hormones, FC fusion proteins, interleukins, and enzymes. Human proteins obtained through genetic engineering play a crucial role in therapeutic medicines.

Get HOLISTIC Request Sample Copy Of This Business Report:
https://www.coherentmarketinsights.com/insight/request-sample/2383

Currently, most of all recombinant therapeutic proteins are produced in mammalian cells, mammalian cells are capable of producing high-quality proteins similar to the naturally occurring ones. Furthermore, many approved recombinant therapeutic proteins are generated in E. coli. (Bacteria) due to its well-characterized genetics, rapid growth, and high-yield production.

Pharmaceutical companies are progressively focusing on research using proteins to develop novel effective therapeutics. Advances in molecular control of gene expression are also expanding the opportunities for protein expression systems. The next generation expression systems are gaining traction as drug manufacturers are looking for cheaper ways to express new biologic drugs. For instance, on 6 December 2018, AMSBIO introduced ALiCE, a new high-yield cell-free protein expression system. ALiCE is a unique eukaryotic system, which yields an unprecedented 3 mg/ml of protein in batch mode.

Rising incidence of various diseases such as cancer, cardiovascular conditions, and genetic disorders is the major factor driving growth of protein expression system market. For instance, protein-based drugs such as insulin, can treat a wide variety of conditions with remarkable effectiveness. Moreover, high efficiency of protein therapeutics and minimum risk of side effects associated with protein therapeutics is attracting manufacturers to invest in the protein expression systems research and development. Recombinant proteins such as enzymes and biologics are useful in the biopharmaceutical, chemical, and food industries.

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/2383

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.